Imedex: Education is the Best Medicine®

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

3rd Annual Perspectives in Genitourinary Oncology: A Case-based Approach to Enhance Patient Management of Prostate, Renal and Bladder Cancers

September 11-12, 2009

Chicago, Illinois

The Westin Michigan Avenue

Continuing Medical Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 13.0 of AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Who Should Attend

This conference is intended for medical oncologists, radiation oncologists, surgeons, urologists, and other healthcare providers involved or interested in the management of prostate, renal, and bladder cancers.

Objectives

After completing this educational activity, participants should be able to:

Comment on current trends to improve the diagnosis and prognosis of prostate, renal, and bladder cancers
Recommend treatment modalities and emerging therapeutic approaches based on assimilation of expert guided case presentations
Implement state-of-the-art surgical advancements in prostate, renal, and bladder cancers
Discuss the optimal management of patients with rising PSA levels or PSA failure
Outline a treatment algorithm for patients with castration-resistant prostate cancer
Apply most recent techniques and emerging therapies to effectively manage noninvasive bladder cancer
Based on knowledge of recent clinical trials, discuss the timing of surgery and chemotherapy,selection of optimal salvage therapy, and management of patients with co-morbidities for patients with advanced bladder cancer
Recommend the most effective approach to treat patients with localized renal cell carcinoma including small renal masses
Highlight most recent first- and second- line therapeutic advances for the clinical management of patients with advanced or metastatic renal cancer
Evaluate the most clinically relevant data presented at The 2009 Annual Oncology Meeting and The Annual Urologic Association Meeting
Integrate therapeutic advances into treatment protocols for patients with testicular cancer

Alan Pollack, MD, PhD
University of Miami School of Medicine
Miami, Florida

Dean F. Bajorin, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Steven C. Campbell, MD, PhD
Cleveland Clinic
Cleveland, Ohio

Robert Dreicer, MD, FACP
Taussig Cancer Institute Cleveland Clinic
Cleveland, Ohio

Laurence Klotz, MD
University of Toronto
Toronto, Ontario, Canada

Brian I. Rini, MD
Cleveland Clinic
Cleveland, Ohio

Arthur I. Sagalowsky, MD
University of Texas Southwestern Medical Center
Dallas, Texas

Mark S. Soloway, MD
University of Miami School of Medicine
Miami, Florida

Walter M. Stadler, MD
University of Chicago Medical Center
Chicago, Illinois

Gary Steinberg, MD
University of Chicago
Chicago, Illinois

New this year: Concurrent break-out discussions for oncologists and urologists on the management of prostate,bladder, and renal cancers.

Friday, September 11, 2009

8:00 am
Welcome and introduction
Mark S. Soloway, MD

Session I: Prostate Cancer
Moderator: Mark S. Soloway, MD

8:05 am
Alternative treatments for low risk prostate cancer including active surveillance
Laurence Klotz, MD

8:25 am
Role of radiation therapy for clinically localized prostate cancer
Alan Pollack, MD, PhD

8:45 am
Questions

8:55 am
Expert Discussion
Moderator: Mark S. Soloway, MD

Panel: Dean F. Bajorin, MD, Robert Dreicer, MD, FACP, Laurence Klotz, MD, and Alan Pollack, MD, PhD

Cases:

#1: Low risk patient
#2: Locally advanced patient
#3: PSA failure patient post surgery
#4: Rising PSA following radiation therapy
#5: Consideration for prostate cancer prevention

10:00 am
Coffee break

Break Out Discussions in Prostate Cancer

Discussion 1: Management of low & intermediate risk prostate cancer

10:20 am
Expert Case Discussion
Moderator: Mark S. Soloway, MD

Panel: Steven C. Campbell, MD, PhD, Laurence Klotz, MD, Arthur I. Sagalowsky, MD, and Alan Pollack, MD, PhD

Cases:

#1: Technical aspects of patient to have prostatectomy for cT1 – 2 prostate cancer
#2: Elevated PSA and negative prostate biopsy. Role of additional biopsies, MRI, other markers,etc
#3: Salvage therapy for patient after radiation and now rising PSA
#4: Role of HIFU and cryotherapy for low risk prostate cancer

Discussion 2: Management of advanced prostate cancer

10:20 am
Managing PSA failure patients referred from urology Robert Dreicer, MD, FACP

10:40 am
Expert Case Discussion
Moderator: Robert Dreicer, MD, FACP

Panel: Dean F. Bajorin, MD and Brian I. Rini, MD

Cases:

#1: PSA progression in the castrate setting, no evidence of metastases
- I ssues: when to image, role of PSA kinetics, role/rational of second line hormonal therapy and potential new agents i.e. abiraterone
#2: Patient with asymptomatic castrate progressive disease
- I ssues: When to start docetaxel, how long to treat, bisphosphonate use
# 3: Patient with moderate symptoms post docetaxel: role of salvage therapy, second line hormonal agents, retreatment with docetaxel other agents, investigational options

12:00 pm
Lunch break: Meet the professor

Session II: Bladder Cancer
Moderator: Mark S. Soloway, MD

1:00 pm
Management of locally advanced bladder cancer
Dean F. Bajorin, MD

1:20 pm
Novel emerging therapies for bladder cancer
Robert Dreicer, MD, FACP

1:40 pm
Questions

1:50 pm
Expert Case Discussion
Moderator: Mark S. Soloway, MD

Panel: Dean F. Bajorin, MD, Steven C. Campbell, MD, PhD, Robert Dreicer, MD, FACP, and Arthur I. Sagalowsky, MD

Cases:

#1: BCG failure patient
#2: Locally advanced patient with obvious pelvic nodal disease
#3: High grade T2 with a lymphovascular invasion
#4: Small cell bladder cancer

3:00 pm
Coffee break

Break Out Discussions in Bladder Cancer

Discussion 1: Management of low & moderate risk bladder cancer

3:20 pm Expert Discussion
Moderator: Mark S. Soloway, MD

Panel: Steven C. Campbell, MD, PhD, Arthur I. Sagalowsky, MD,and Gary Steinberg, MD

Cases:

#1: Recurrent low grade Ta after TUR BT
#2: Recurrent HG T1 TCC after BCG
#3: TCC of the upper urinary tract, low grade biopsy
#4: Adenocarcinoma of the bladder

Discussion 2: Management of advanced bladder cancer

3:20 pm
Expert Discussion
Moderator: Robert Dreicer, MD, FACP

Panel: Dean F. Bajorin, MD

Cases:

#1: Locally advanced patient with renal compromise
- I ssue: Decision making regarding therapy in unfit patients
#2: Renal pelvis TCC with regional nodes, role time of surgery and chemotherapy
#3: Advanced disease patient progressed after front-line chemotherapy Issue: How to select optimal salvage therapy

4:30 pm
Adjourn

Saturday, September 12, 2009

8:00 am
Welcome and introduction
Robert Dreicer, MD, FACP

Session II: Renal Cancer
Moderator: Robert Dreicer, MD, FACP

8:05 am
Management of small renal masses
Steven C. Campbell, MD, PhD

8:25 am
Therapeutic management of locally advanced renal cancer
Brian I. Rini, MD

8:45 am
Questions

8:55 am
Expert Discussion
Moderator: Mark S. Soloway, MD

Panel: Steven C. Campbell, MD, PhD, Robert Dreicer, MD, FACP, Brian I. Rini, MD, and Walter M. Stadler, MD

Cases:

#1: Small renal lesions
#2: Locally advanced clear cell carcinoma
#3: Patient with minimal metastatic disease
#4: Patient with resected T2B with and without positive lymph nodes

10:00 am
Coffee break

Break Out Discussions in Renal Cancer

Discussion 1: Management of low & moderate risk renal cancer

10:20 am
Expert Discussion
Moderator: Mark S. Soloway, MD

Panel: Steven C. Campbell, MD, PhD

Cases:

#1: Technical aspects of renal cell carcinoma with involvement of the vena cava
#2: Open versus laparoscopic partial nephrectomy
#3: Bilateral renal tumors
#4: Complex cyst - role of biopsy

Discussion 2: Management of advanced renal cancer

10:20 am
Current status of front line therapy for management of advanced renal cancer patients
Brian I. Rini, MD

10:40 am
Expert Discussion
Moderator: Robert Dreicer, MD, FACP

Panel: Brian I. Rini, MD and Walter M. Stadler, MD

Cases:

#1: Metastatic clear cell patient, disease progression on front line TKI
- I ssues: role/rationale data for second line therapy, dosing issues of TKI, role of mTOR in second line
#2: Metastatic clear cell patient develops toxicity with TKI managing toxicity of TKI, dose, dose escalation issues
#3: Patient with metastatic clear cell renal cancer, response to bevacizumab/interferon Issue: Integrating surgery following response in the metastatic setting

12:00 pm Lunch break

Session IV: Highlights from 2008 Meetings

Moderator: Robert Dreicer, MD, FACP

1:00 pm
Highlights from AUA
Steven C. Campbell, MD, PhD

1:30 pm
Highlights from The Annual Oncology Meeting
Walter M. Stadler, MD

2:00 pm
Questions

2:10 pm
Coffee break

Session V: Testis Cancer

Moderator: Mark S. Soloway, MD

2:30 pm
State of the art on testis tumor from urologist perspective
Arthur I. Sagalowsky, MD

2:50 pm
Expert Discussion
Moderator: Mark S. Soloway, MD

Panel: Robert Dreicer, MD, FACP and Arthur I. Sagalowsky, MD

Cases:

#1: II C seminoma, managing the residual mass
#2: Growing teratoma s/p chemotherapy for intermediate risk NSGCT
#3: Missed node in landing zone growing over the years
#4: NCGCT managing opposite testes with microcalcifications

4:00 pm
Adjourn

Information coming soon.

Registration Fees

Discounted $245
If payment received by July 7, 2009

Regular $345
If payment received by September 3, 2009

Full/Onsite $445
If payment received after September 3, 2009

Group discount -$50
*cannot be combined with any other discounts

Nurses, Fellows, Resident $99
*proof of eligibility must accompany registration (physicians only)*

To Register: You may register online by September 3, 2009 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this program by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available for nurses, residents or students.

Payment: To pre-register, registration and payment must be received no later than September 3, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www. imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in this announcement.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex. com no later than September 3, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after September 3, 2009.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

The Westin Michigan Avenue
909 N. Michigan Avenue
Chicago, Illinois 60611
Tel.: +1 (312) 943 7200
Fax: +1 (312) 397 5580
http://www.thewestinmichiganavenue.com/

The Westin Michigan Avenue is located on Chicago’s famed Magnificent Mile steps from Lake Michigan, award-winning restaurants and premier shopping. Plus, the hotel is within walking distance to the midwest’s most popular tourist and leisure destination, Navy Pier. Get immersed in the unique culture of Chicago and let The Westin Michigan Avenue transcend your next visit to the Windy City.

The Westin Michigan Avenue has 751 guest rooms including 23 suites, each with a marble foyer and large marble bathroom. Enjoy the comforts of home and technology like dual line telephones, in room internet and wireless hotspots in the lobby.

For the convenience of attendees, a limited number of rooms have been reserved until August 14, 2009 at a discounted rate of $269 single/double occupancy, plus tax, currently at 15.4%. This rate is not guaranteed outside the conference dates or after August 14, 2009.

To reserve your room please contact the Westin Michigan Avenue reservations department at +1 (312) 943 7200 or visit the hotel’s website at http://www.thewestinmichiganavenue.com/. To receive the group rate, callers must identify themselves as being with the Perspectives in Genitourinary Oncology group. Reservation requests received after August 14, 2009 may not be guaranteed the group rate.

Dear Colleagues,

It is with great pleasure that we invite you to attend the 3rd Annual Perspectives in Genitourinary Oncology: A Case-Based Approach to Enhance Patient Management of Prostate, Renal, and Bladder Cancers, to be held September 11-12, 2009 in Chicago, Illinois. This conference will be a forum where medical/radiation oncologists and urologists can come together to learn and share their clinical experiences through both didactic lectures and interactive case discussions. Our panel of experts will touch on the most significant aspects of prostate, renal, and bladder cancers. They will discuss the status of the latest treatment modalities as well as emerging therapeutic approaches. The meeting will delve into the areas of controversy through vigorous discussion and debate using information from clinical trials as applicable. The speakers have all been selected due to their strong therapy area experience and ability to communicate effectively. Our ultimate goal is to provide you with the information needed to optimize patient care and to make you aware of pertinent current trends and evolutions. After this meeting, attendees will be able to implement state-of-the art surgical advancements in renal, bladder, and prostate cancers, and recommend treatment modalities and emerging therapeutic approaches based on assimilation of expert-guided case presentations. We hope you will join us in Chicago for what is sure to be an outstanding interactive event with many lively discussions!

Sincerely,
Robert Dreicer, MD, FACP
Mark S. Soloway, MD

ORGANIZER

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

The following companies have provided an educational grant in support of this conference:

SILVER

BRONZE

CORPORATE

Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.

The following company is an exhibitor at this conference:

Opportunities are available to companies interested in exhibiting at this conference. For more information, please contact Cori Gunter at +1(678) 242 0712, or by email at c.gunter@imedex.com.